Phase I, Open Label Dose-Escalation Study To Evaluate The Safety, Expansion, Persistence And Clinical Activity Of UCARTCS1A (Allogeneic Engineered T-Cells Expressing Anti-CS1 Chimeric Antigen Receptor), Administered In Patients With Relapsed/Refractory Multiple Myeloma Read more
A Phase 2, Multicohort Open-Label Study Of JNJ-68284528, A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA In Subjects With Multiple Myeloma (CARTITUDE 2) Read more
A Phase II Study Of Venetoclax And Rituximab/Hyaluronidase Human In Relapsed/Refractory CLL Read more
A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Axicabtagene Ciloleucel In Combination With Either Rituximab Or Lenalidomide In Subjects With Refractory Large B-Cell Lymphoma (ZUMA-14) Read more
A Prospective, Open-Label, Multicenter Randomized Phase III Study To Compare The Efficacy And Safety Of A Combined Regimen Of Venetoclax And Obinutuzumab Versus Fludarabine, Cyclophosphamide, And Rituximab (FCR)/Bendamustine And Rituximab (BR) In FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL(17P) Or TP53 Mutation Read more
A Phase 2 Study To Evaluate The Efficacy And Safety Of MK-1026 In Participants With Hematologic Malignancies Read more
